Elucid, a Boston, MA-company developing non-invasive medical software to characterize cardiovascular disease, raised $27M in Series B funding.
The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, and existing investors, including MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners.
The company intends to use the funds to accelerate growth and its development efforts.
Led by CEO Blake Richards, Elucid is a medical technology company using interpretable and validated AI to provide physicians with a software platform to optimize treatment decisions for patients with cardiovascular disease. The FDA-Cleared and CE-marked non-invasive software quantifies atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core.
Specifically, the algorithms developed through machine learning characterize tissue types in the artery wall known to cause heart attacks, such as lipid rich necrotic core. The capability to discern complex plaque biology at the cellular and molecular level is powering new applications that can derive fractional flow reserve (FFRct), risk of heart attack/stroke, and expression prediction to inform therapeutic selection.
This approach enables physicians to diagnose the direct cause of chest pain but also to determine if patients have early-stage heart disease which cannot be seen by alternative methods.
The software is available for commercial use in the U.S., Europe, and South Korea.